Finland· FI-REL-REL28315
Enviage
A aliskiren product containing aliskiren hemifumarate, registered in Finland by Novartis Europharm Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Aliskiren is registered in 13 of 19 countries.
Countries holding a registration under ATC C09XA02 (aliskiren), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Aliskiren · ATC C09XA02
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of aliskiren costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.95 in Italy to $3.43 in United States — a ×3.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Aliskiren · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- US United States$3.43 (acquisition cost)
- IT Italy$0.95
The record
At a glance
Fimea (Finland)- Active substance
- Aliskiren hemifumarate
- Manufacturer
- Novartis Europharm Ltd
- Country
- Finland (FI)
- ATC code
- C09XA02
- ATC class
- Aliskiren
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
227 interactions on record for aliskiren.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aliskiren · interactions on record
227 records
- 1 severe
- 147 moderate
- 26 info
Most severe, free to view
- CiclosporinL04AD01severe
- ClotrimazoleA01AB18moderate
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
53 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aliskiren in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7b23a90c-0ef5-4b24-a793-d867ddb2c6cb GET /v1/drugs/7b23a90c-0ef5-4b24-a793-d867ddb2c6cb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.15",
"form": "tabletti, kalvopäällysteinen",
"route": null,
"ddd_unit": "g",
"strength": "300 mg",
"atc_label": "aliskireeni",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/07/406/011-020",
"fimea_rel_id": "REL28315",
"authorised_at": "2007-08-22"
}See everything about aliskiren.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.